Affibody Molecules as Targeting Vectors for PET Imaging; Cancers; Vol. 12, iss. 3

Affibody Molecules as Targeting Vectors for PET Imaging; Cancers; Vol. 12, iss. 3

Podrobná bibliografie
Parent link:	Cancers Vol. 12, iss. 3.— 2020.— [651, 21 p.]
Hlavní autor:	Tolmachev V. M. Vladimir Maksimilianovich
Korporativní autor:	Национальный исследовательский Томский политехнический университет Исследовательская школа химических и биомедицинских технологий Научно-исследовательский центр "Онкотераностика"
Další autoři:	Orlova A. M. Anna Markovna
Shrnutí:	Title screen Affibody molecules are small (58 amino acids) engineered scaffold proteins that can be selected to bind to a large variety of proteins with a high affinity. Their small size and high affinity make them attractive as targeting vectors for molecular imaging. High-affinity affibody binders have been selected for several cancer-associated molecular targets. Preclinical studies have shown that radiolabeled affibody molecules can provide highly specific and sensitive imaging on the day of injection; however, for a few targets, imaging on the next day further increased the imaging sensitivity. A phase I/II clinical trial showed that 68Ga-labeled affibody molecules permit an accurate and specific measurement of HER2 expression in breast cancer metastases. This paper provides an overview of the factors influencing the biodistribution and targeting properties of affibody molecules and the chemistry of their labeling using positron emitters.
Jazyk:	angličtina
Vydáno:	2020
Témata:	электронный ресурс труды учёных ТПУ PET affibody molecules HER2 EGFR molecular imaging radiolabeling
On-line přístup:	https://doi.org/10.3390/cancers12030651
Médium:	Elektronický zdroj Kapitola
KOHA link:	https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=664970

Podobné jednotky

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules; International Journal of Molecular Sciences; Vol. 21, iss. 6
Vydáno: (2020)

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer; EJNMMI Research; Vol. 10, iss. 1
Vydáno: (2020)

Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake; International Journal of Molecular Sciences; Vol. 22, iss. 5
Vydáno: (2021)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules; International Journal of Molecular Sciences; Vol. 21, iss. 4
Vydáno: (2020)

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab; Cancers; Vol. 15 - iss. 9
Vydáno: (2023)

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model; Pharmaceutics; Vol. 12, iss. 6
Vydáno: (2020)

Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs; Journal of Controlled Release; Vol. 355
Vydáno: (2023)

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model; Cancers; Vol. 13, iss. 1
Vydáno: (2020)

Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation; Journal of Controlled Release; Vol. 370
Vydáno: (2024)

Comparative Preclinical Evaluation of the Tumor-Targeting Properties of Radioiodine and Technetium-Labeled Designed Ankyrin Repeat Proteins for Imaging of Epidermal Growth Factor Receptor Expression in Malignant Tumors; International Journal of Molecular Sciences; Vol. 26, iss. 21
Vydáno: (2025)

HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution; Pharmaceutics; Vol. 12, iss. 4
Vydáno: (2020)

Phase I clinical evaluation of 99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer; Theranostics; Vol. 13, iss. 14
Vydáno: (2023)

Radiolabeling Strategies of Micron- and Submicron-Sized Core–Shell Carriers for In Vivo Studies; ACS Applied Materials and Interfaces; Vol. 12, iss. 28
Vydáno: (2020)

Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3; Nuclear Medicine and Biology; Vol. 124-125
Vydáno: (2023)

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer; Cancers; Vol. 15 - iss. 12
Vydáno: (2023)

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer; Molecules; Vol. 25, iss. 24
Vydáno: (2020)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model; Pharmaceutics; Vol. 12, iss. 7
Vydáno: (2020)

Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1; Molecules; Vol. 25, iss. 20
Vydáno: (2020)

Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors; Molecular Pharmaceutics; Vol. 21, iss. 4
Vydáno: (2024)

Mass Spectrometry Imaging of Small Molecules Methods and Protocols /
Vydáno: (2022)

The position of 99mTc-HYNIC and the molecular design of the DARPin G3 constructs influence the selection of an imaging tracer to detect expression in HER2-expressing tumors; Journal of Radioanalytical and Nuclear Chemistry; Vol. 335
Vydáno: (2026)

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape; Cancers; Vol. 12, iss. 10
Vydáno: (2020)

Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1; International Journal of Molecular Sciences; Vol. 21, iss. 9
Vydáno: (2020)

Protein-Protein Docking Methods and Protocols /
Vydáno: (2024)

Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?; Pharmaceutics; Vol. 17, iss. 10
Vydáno: (2025)

Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion; International Journal of Molecular Sciences; Vol. 25, iss. 8
Vydáno: (2024)

The Use of Glycine-Containing Peptide-Based Chelators for Labeling with 99mTc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1; Molecular Pharmaceutics; Vol. 23, iss. 4
Vydáno: (2026)

Analysis of the Ground Vibrational State of the Ethylene-1-13C (13C12CH4) Molecule; Russian Physics Journal; Vol. 60, iss. 2
Vydáno: (2017)

Analysis of high-resolution spectra of SiF4 combination bands; Journal of Molecular Spectroscopy; Vol. 391
Autor: Merkulova M. A. Maria Andreevna
Vydáno: (2023)

Cancer Cytogenetics Methods and Protocols /
Vydáno: (2011)

Magnetic Control of Tokamak Plasmas
Autor: Ariola, Marco, a další
Vydáno: (2016)

Cancer Epigenetics Risk Assessment, Diagnosis, Treatment, and Prognosis /
Vydáno: (2015)

Cancer Gene Profiling Methods and Protocols /
Vydáno: (2016)

Cancer Gene Profiling Methods and Protocols /
Vydáno: (2010)

RNA Imaging Methods and Protocols /
Vydáno: (2016)

Philosophy of Astrophysics Stars, Simulations, and the Struggle to Determine What is Out There /
Vydáno: (2023)

Imaging Gene Expression Methods and Protocols /
Vydáno: (2013)

Target Identification and Validation in Drug Discovery Methods and Protocols /
Vydáno: (2025)

Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin; Pharmaceutics; Vol. 11, iss. 5
Vydáno: (2019)

Ресайклинг синтетических волокон и тканей химическим методом; Перспективы развития фундаментальных наук; Т. 2 : Химия
Autor: Манапова Е. Э.
Vydáno: (2025)